L. Juntti-berggren et al., Influence of acarbose on post-prandial insulin requirements in patients with Type 1 diabetes, DIABET NUTR, 13(1), 2000, pp. 7-12
The primary objective of this double-blind, placebo-controlled, randomised
cross-over study was to investigate the influence of acarbose on insulin re
quirement in patients with Type 1 diabetes (TIDM) following a standardised
meal. Tn addition, the study assessed the effects of acarbose on post-prand
ial triglyceride, glucagon and gastrointestinal peptide levels, gastric emp
tying, and oxidative glucose metabolism, Following normalisation of their b
lood glucose, 10 patients received a standardised meal together with acarbo
se (100 mg) or placebo. Each patient was evaluated twice (separated by 10+/
-3 days), and the crossover study design ensured that they received both ac
arbose and placebo. The insulin requirement for maintenance of normoglycaem
ia was assessed using a closed-loop insulin infusion system (artificial pan
creas, Biostator(R)), Acarbose produced a statistically significant reducti
on in mean insulin requirement over a 3-hr period following the meal compar
ed with placebo (5171.7+/-2282.6 mU vs 8074.5+/-3045.4 mU; p=0.003). The le
vel of blood glucose control over the same period was similar in the two gr
oups. Gastric inhibitory polypeptide levels also showed a statistically sig
nificant decrease with acarbose treatment compared with placebo for AUC (ar
ea under the curve; p=0.006) and C-max (maximum plasma concentration; p=0.0
22), but not t(max) (time to reach C-max from the start of the standardised
meal; p>0.05). Analysis of the other efficacy parameters revealed no stati
stically significant differences between acarbose treatment and placebo (p>
0.05). These results indicate that acarbose decreases insulin requirement i
n patients with T1DM without affecting gastric emptying, Diab. Nutr. Metab.
13:7-12, 2000. (C) 2000, Editrice Kurtis.